每经AI快讯，威高血净（SH 603014，收盘价：39.85元）9月15日晚间发布公告称，公司第二届第十四 次董事会会议于2025年9月15日在公司会议室召开。会议审议了《关于选举山东威高血液净化制品股份 有限公司董事会薪酬与考核委员会委员的议案》等文件。 每经头条（nbdtoutiao）——重大突破！中国这款新药，中美官方都认定有突破性疗效！世界肺癌大会 沸腾了 （记者 王晓波） 2025年1至6月份，威高血净的营业收入构成为：耗材类占比77.55%，设备类占比18.25%，其他业务占 比2.35%，其他占比1.85%。 截至发稿，威高血净市值为164亿元。 ...

Group 1 - The core point of the article is that Jiet Biotech (SH 688026) held its 23rd meeting of the fourth board on August 28, 2025, to review the semi-annual evaluation report of the 2025 quality improvement and efficiency enhancement action plan [1] - For the fiscal year 2024, Jiet Biotech's revenue composition shows that consumables account for 95.02% of total revenue, while other businesses contribute 4.98% [1] - As of the report date, Jiet Biotech has a market capitalization of 2.7 billion yuan [1]

Group 1 - The company Jiet Biotech announced the resignation of its board secretary, Ge Jingbo, due to personal reasons, and he will no longer hold any position within the company after his resignation [2] - For the fiscal year 2024, Jiet Biotech's revenue composition is as follows: consumables account for 95.02% of total revenue, while other business segments contribute 4.98% [2]